Wedbush Downgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Neutral

Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) was downgraded by equities researchers at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Tuesday, Briefing.com reports. A number of other analysts also recently weighed in on the stock. Stifel Nicolaus reduced their target price on shares of Black Diamond Therapeutics from […]

Related Keywords

Stifel Nicolaus ,Morgan Stanley ,Geode Capital Management ,Diamond Therapeutics Inc ,Zacks Investment Research ,Renaissance Technologies ,Blackrock Inc ,Black Diamond Therapeutics ,Get Rating ,Investment Research ,Diamond Therapeutics ,Capital Management ,State Street Corp ,Street Corp ,Nasdaq Bdtx ,Bdtx ,Medical ,Downgrade ,Wedbush ,